Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma Announces Financial Results for the First Half of 2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all…
Pharma firms obliged to make medicines even if unprofitable - Opinion
Man buys medicine with the help of a pharmacy sales person in Chongqing municipality, Southwest China, July 21, 2014. [Photo/IC] AFTER MEDIA REPORTS about a shortage, even in some big hospitals, of mercapatopurinem, a medication used to treat…
Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
Placement on two elite stock screens and promising technical indicators put Ligand Pharmaceuticals (LGND) in focus. Ligand stock has landed a spot on the IBD 50 and the latest list of new buys by the best mutual funds. The monthly screen showed…
Swiss pharma group warns medicine access is worsening
A survey of member companies has shown that pharmaceutical manufacturers no longer consider themselves able, under the current framework, to launch new therapies in Switzerland in a timely manner without jeopardising prices in the US, Interpharma…
India's Q1 pharma exports up 6.8% to $8.1bn; U.S. remains largest export destination
India's pharmaceutical exports rose 6.8% year-on-year (YoY) to $8.1 billion in the first quarter (Q1) ended June, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil). Drug formulations and biologicals exports stood at…
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
WVE sits 69% below its yearly high at a $1 billion market cap, with obesity drug WVE-007 showing visceral fat cuts and muscle preservation. GSK leads plausible acquirers given its existing WVE-006 partnership, while LLY could attach WVE-007 to…
Ascendis Pharma A/S Q2 Earnings Call Highlights
Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/ S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial…
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4%
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 135,370 shares, an increase of 223.4% from the July 15th total…
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings
Shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $39.99 and last traded at $37.38, with…
Haypp Group, Terravest Industries, Zedcor Inc, Delcath, and Moberg Pharma report
When Haypp Group decides to prioritize earnings instead of growth, they will make a lot of money. They are obviously still trying to grow as fast as they can. Ironically if they stay in this growth state forever the shares would probably continue…
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX)
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic…
GoodRx (GDRX) Q2 2026 Earnings Call Transcript
Thursday, Aug. 6, 2026 at 8 a.m. ET Director of Investor Relations - Aubrey Reynolds Chief Executive Officer - Wendy Barnes Chief Financial Officer - Justin Fengler Revenue -- $200.4 million, representing a 1% decline reflecting a strategic shift…
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma. The…
Medicare Part D: The cost of ending drug subsidies
Millions of older Americans who are already struggling with rising gas and food prices will soon have to pay more for prescription drugs, said Anna Wilde Mathews in The Wall Street Journal. The Trump administration announced last week that it is…
KORU (KRMD) Q2 2026 Earnings Call Transcript
Wednesday, Aug. 5, 2026 at 4:30 p.m. ET President and Chief Executive Officer - Adam Kalbermatten Chief Financial Officer - Thomas Adams Investor Relations - Louisa Smith Net Revenues -- $12.0 million, representing a 18.2% increase year over year…
Receive a Daily briefing on Pharma Industry News
Get Started